Literature DB >> 33767709

Current Advance of Immune Evasion Mechanisms and Emerging Immunotherapies in Renal Cell Carcinoma.

Yuli Jian1, Kangkang Yang1, Xiaoxin Sun1, Jun Zhao2, Kai Huang2, Abdullah Aldanakh2, Zhongyang Xu1, Haotian Wu2, Qiwei Xu1, Lin Zhang1, Chunyan Xu1, Deyong Yang2, Shujing Wang1.   

Abstract

Renal cell carcinoma is a highly heterogeneous cancer group, and the complex microenvironment of the tumor provides appropriate immune evasion opportunities. The molecular mechanism of immune escape in renal cell carcinoma is currently a hot issue, focusing primarily on the major complex of histocompatibility, immunosuppressive cells, their secreted immunosuppressive cytokines, and apoptosis molecule signal transduction. Immunotherapy is the best treatment option for patients with metastatic or advanced renal cell carcinoma and combination immunotherapy based on a variety of principles has shown promising prospects. Comprehensive and in-depth knowledge of the molecular mechanism of immune escape in renal cell carcinoma is of vital importance for the clinical implementation of effective therapies. The goal of this review is to address research into the mechanisms of immune escape in renal cell carcinoma and the use of the latest immunotherapy. In addition, we are all looking forward to the latest frontiers of experimental combination immunotherapy.
Copyright © 2021 Jian, Yang, Sun, Zhao, Huang, Aldanakh, Xu, Wu, Xu, Zhang, Xu, Yang and Wang.

Entities:  

Keywords:  immune checkpoint; immunotherapy; renal cell carcinoma; tumor immune evasion; tumor microenvironment

Year:  2021        PMID: 33767709      PMCID: PMC7985340          DOI: 10.3389/fimmu.2021.639636

Source DB:  PubMed          Journal:  Front Immunol        ISSN: 1664-3224            Impact factor:   7.561


  8 in total

1.  A Novel Prognostic Signature Associated With the Tumor Microenvironment in Kidney Renal Clear Cell Carcinoma.

Authors:  Dongchen Pei; Chaojie Xu; Dong Wang; Xiaoxue Shi; Yurui Zhang; Yi Liu; Jianhua Guo; Nan Liu; Haipeng Zhu
Journal:  Front Oncol       Date:  2022-07-04       Impact factor: 5.738

2.  ADAM metallopeptidase domain 12 overexpression correlates with prognosis and immune cell infiltration in clear cell renal cell carcinoma.

Authors:  Junjie Gao; Dandan Yang; Haonan Xu; Kunpeng Yang; Jia Ma; Jun Xia; Xueshan Pan
Journal:  Bioengineered       Date:  2022-02       Impact factor: 3.269

3.  Systematic Analysis of the Expression and Prognosis of Fcγ Receptors in Clear Cell Renal Cell Carcinoma.

Authors:  Wenyuan Nie; Yong Yao; Benjun Luo; Jiyin Zhu; Shaocheng Li; Xiaoteng Yang; Tao Luo; Wei Liu; Shibing Yan
Journal:  Front Oncol       Date:  2022-03-17       Impact factor: 6.244

Review 4.  The Role of Androgen Receptor and microRNA Interactions in Androgen-Dependent Diseases.

Authors:  Agnieszka Bielska; Anna Skwarska; Adam Kretowski; Magdalena Niemira
Journal:  Int J Mol Sci       Date:  2022-01-28       Impact factor: 5.923

5.  MiRNA-148a inhibits cell growth and drug resistance by regulating WNT10a expression in renal cell carcinoma.

Authors:  Yongsheng Chen; Wenhua Liu; Dechao Li; Yan Cao; Wentao Wang; Changfu Li; Ruihua An
Journal:  Transl Androl Urol       Date:  2022-07

6.  A novel necroptosis-related lncRNAs signature for survival prediction in clear cell renal cell carcinoma.

Authors:  Liwen Zhao; Huaijing Luo; Xingmo Dong; Zhihui Zeng; Jianlong Zhang; Yi Yi; Chaolu Lin
Journal:  Medicine (Baltimore)       Date:  2022-09-30       Impact factor: 1.817

7.  Curcumin reverses the sunitinib resistance in clear cell renal cell carcinoma (ccRCC) through the induction of ferroptosis via the ADAMTS18 gene.

Authors:  Ben Xu; Wei-Jie Zhu; Yi-Ji Peng; Si-Da Cheng
Journal:  Transl Cancer Res       Date:  2021-07       Impact factor: 1.241

8.  Effects of HMGA2 gene silencing on cell cycle and apoptosis in the metastatic renal carcinoma cell line ACHN.

Authors:  Qian Chen; Qizhong Fu; Lin Pu; Xianfeng Liu; Ying Liu
Journal:  J Int Med Res       Date:  2022-02       Impact factor: 1.671

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.